WAT

Waters Corporation (WAT) - Q3 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 27, 2025. Waters Corporation is a global leader in analytical instruments and software, primarily serving life sciences, materials, and food sciences through its Waters and TA Instruments segments. The company designs, manufactures, and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), mass spectrometry (MS), and thermal analysis systems.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total net sales increased 8% in Q3 and 7% YTD, driven by strong demand for Waters Division products. Instrument system sales grew 6% (Q3) and 8% (YTD). Recurring revenues (consumables and services) grew 10% (Q3) and 8% (YTD).
• Operating Income Decline: Q3 operating income decreased 9% year-over-year. This was primarily due to higher transaction and integration costs (~$31 million) associated with the pending BD Merger, merit increases, and $6 million in expenses for a new ERP system implementation.
• Expense Increases: Selling and administrative expenses rose 27% in Q3, largely due to the aforementioned merger costs and ERP implementation. R&D expenses increased 18% due to merit compensation and new product development.
• Debt Reduction: Total debt decreased from $1.63 billion at year-end 2024 to $1.41 billion in Q3 2025, reflecting debt repayments.
• Acquisition: Completed the acquisition of Halo Labs for $35 million in May 2025 to enhance biopharmaceutical formulation tools.

Guidance, Outlook, and Risks

• Major Merger: On July 13, 2025, Waters entered into a definitive agreement to acquire BD's Biosciences and Diagnostic Solutions business in a Reverse Morris Trust transaction valued at approximately $17.5 billion. The deal is expected to close in Q1 2026, subject to regulatory and shareholder approvals. BD shareholders will own ~39.2% of the combined entity.
• Financing: The transaction involves a $4.0 billion cash distribution to BD, funded by new indebtedness assumed by Waters. A $1.8 billion bridge facility has been committed. Total transaction-related expenses are estimated at $140 million.
• Termination Fee: The Merger Agreement includes a termination fee of $733 million payable by Waters under certain circumstances.
• Tariffs and Geopolitics: The company faces risks from U.S. tariffs on imported goods and retaliatory measures from China. A U.S. government shutdown beginning in October 2025 may delay regulatory approvals for the merger.
• ERP Implementation: The company is implementing a new worldwide ERP system with anticipated total costs of $130 million over three years.

Investor Verification Checklist

• Merger Closing Conditions: Verify the status of regulatory approvals and the timeline for the BD Merger, noting the risk of delays due to the U.S. government shutdown.
• Debt Capacity: Assess the impact of the anticipated $4.0 billion in new debt on the company's leverage ratios and credit rating post-merger.
• Integration Costs: Monitor the run-rate of transaction and integration costs, which significantly impacted Q3 operating margins.
• Tariff Exposure: Evaluate the company's mitigation strategies regarding new U.S. tariffs and supply chain disruptions, particularly in China.
• ERP Transition: Track the progress and cost overruns of the new ERP system implementation, which incurred $14 million in operating costs YTD.